Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1978 1
1980 3
1981 4
1982 3
1983 7
1984 3
1985 7
1986 7
1987 11
1988 15
1989 15
1990 23
1991 11
1992 13
1993 12
1994 7
1995 18
1996 15
1997 12
1998 10
1999 11
2000 19
2001 21
2002 14
2003 22
2004 20
2005 23
2006 32
2007 32
2008 20
2009 22
2010 31
2011 40
2012 36
2013 39
2014 31
2015 35
2016 35
2017 37
2018 33
2019 46
2020 43
2021 44
2022 32
2023 26
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

864 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Ovarian Cancer by FIGO Stage"
Page 1
Ovarian cancer.
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Jayson GC, et al. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21. Lancet. 2014. PMID: 24767708 Review.
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. ...Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surg …
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. ...Most women have advanced …
Management of borderline ovarian tumours.
Gershenson DM. Gershenson DM. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:49-59. doi: 10.1016/j.bpobgyn.2016.09.012. Epub 2016 Oct 3. Best Pract Res Clin Obstet Gynaecol. 2017. PMID: 27780698 Review.
Prognostic factors include the International Federation of Gynecology and Obstetrics (FIGO) stage, presence of peritoneal implants, micropapillary pattern (for serous histology), microinvasion and intra-epithelial carcinoma (for mucinous histology). Approximately 65 …
Prognostic factors include the International Federation of Gynecology and Obstetrics (FIGO) stage, presence of peritoneal impl …
Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance.
Li YK, Zeng T, Guan Y, Liu J, Liao NC, Wang MJ, Chen KX, Luo XY, Chen CY, Quan FF, Wang J, Zhang QF, Zou J. Li YK, et al. Int J Biol Sci. 2023 Jan 1;19(1):258-280. doi: 10.7150/ijbs.66839. eCollection 2023. Int J Biol Sci. 2023. PMID: 36594088 Free PMC article.
Background: Ovarian cancer (OC), a serious gynecological malignant disease, remains an enormous challenge in early diagnosis and medical treatment. ...Next, we confirmed the mRNA and protein levels of ESM1 in OC samples via PCR and IHC. The correlation between the E …
Background: Ovarian cancer (OC), a serious gynecological malignant disease, remains an enormous challenge in early diagnosis a …
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Moore KN, et al. J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891472 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placeb …
PURPOSE: To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-base …
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive su …
BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and …
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. du Bois A, et al. Cancer. 2009 Mar 15;115(6):1234-44. doi: 10.1002/cncr.24149. Cancer. 2009. PMID: 19189349 Free article. Clinical Trial.
BACKGROUND: Primary surgery followed by platinum-taxane based chemotherapy has been the standard therapy in advanced ovarian cancer. However, the prognostic role of complete and so-called optimal and suboptimal debulking and its interaction with biological factors h …
BACKGROUND: Primary surgery followed by platinum-taxane based chemotherapy has been the standard therapy in advanced ovarian cance …
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL, Bryant A, Kehoe S, Morrison J. Coleridge SL, et al. Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6. Cochrane Database Syst Rev. 2021. PMID: 34328210 Free PMC article.
BACKGROUND: Epithelial ovarian cancer presents at an advanced stage in the majority of women. ...The main investigators of relevant trials were contacted for further information. SELECTION CRITERIA: Randomised controlled trials (RCTs) of women with adv …
BACKGROUND: Epithelial ovarian cancer presents at an advanced stage in the majority of women. ...The main investigators …
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. ...Randomis …
BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with th …
Laparoscopy versus laparotomy for FIGO stage I ovarian cancer.
Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, Zelmanowicz A, Moraes AB, Zanini RR, Rosa DD. Falcetta FS, et al. Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005344. doi: 10.1002/14651858.CD005344.pub4. Cochrane Database Syst Rev. 2016. PMID: 27737492 Free PMC article. Review.
OBJECTIVES: To evaluate the benefits and harms of laparoscopy in the surgical treatment of FIGO stage I ovarian cancer (stages Ia, Ib and Ic) when compared with laparotomy. ...For this update we searched CENTRAL, MEDLINE, and Embase from Novembe …
OBJECTIVES: To evaluate the benefits and harms of laparoscopy in the surgical treatment of FIGO stage I ovarian canc …
Advanced ovarian cancer.
van der Burg ME. van der Burg ME. Curr Treat Options Oncol. 2001 Apr;2(2):109-18. doi: 10.1007/s11864-001-0053-1. Curr Treat Options Oncol. 2001. PMID: 12057129 Review.
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical principle, is not possible in patients with high-stage ovarian cancer. ...A multimodality approach with cytoreductive surgery …
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical princip …
864 results